Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020138256 - T-CELL RECEPTOR MODIFIED OBJECT

Publication Number WO/2020/138256
Publication Date 02.07.2020
International Application No. PCT/JP2019/051057
International Filing Date 26.12.2019
IPC
C07K 14/705 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
C12N 5/10 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
10Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
C12N 15/12 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
12Genes encoding animal proteins
C12N 15/63 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
CPC
C07K 14/705
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
C12N 15/63
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
C12N 5/10
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor;
10Cells modified by introduction of foreign genetic material
Applicants
  • 国立大学法人京都大学 KYOTO UNIVERSITY [JP]/[JP]
  • 武田薬品工業株式会社 TAKEDA PHARMACEUTICAL COMPANY LIMITED [JP]/[JP]
Inventors
  • 金子 新 KANEKO, Shin
  • 葛西 義明 KASSAI, Yoshiaki
  • 林 哲 HAYASHI, Akira
Agents
  • 高島 一 TAKASHIMA, Hajime
Priority Data
2018-24525327.12.2018JP
Publication Language Japanese (JA)
Filing Language Japanese (JA)
Designated States
Title
(EN) T-CELL RECEPTOR MODIFIED OBJECT
(FR) OBJET MODIFIÉ PAR UN RÉCEPTEUR DE LYMPHOCYTES T
(JA) T細胞受容体の改変体
Abstract
(EN)
The present invention provides a T-cell receptor modified object formed by combining two polypeptides including the constant region of a T-cell receptor chain selected from the group consisting of α-chain, β-chain, γ-chain, and δ-chain, the modified object being characterized in that the polypeptides do not include a complementarity determining region (CDR) of the T-cell receptor chain, a complementarity determining region (CDR) of α-chain, and a complementarity determining region (CDR) of β-chain.
(FR)
La présente invention concerne un objet modifié par un récepteur de lymphocytes T formé par combinaison de deux polypeptides comprenant une région constante d'une chaîne de récepteurs de lymphocytes T choisie dans le groupe constitué par la chaîne α, la chaîne β, la chaîne γ et la chaîne δ, l'objet modifié étant caractérisé en ce que les polypeptides ne comprennent pas une région déterminant la complémentarité (CDR) de la chaîne du récepteurs de lymphocytes T, une région déterminant la complémentarité (CDR) de chaîne α, et une région déterminant la complémentarité (CDR) de chaîne β.
(JA)
本発明は、α鎖、β鎖、γ鎖及びδ鎖からなる群から選択されるT細胞受容体鎖の定常領域を含むポリペプチドを2つ組み合わせてなる、T細胞受容体の改変体であって、該ポリペプチドが該T細胞受容体鎖の相補性決定領域(CDR)、α鎖の相補性決定領域(CDR)およびβ鎖の相補性決定領域(CDR)を含まないことを特徴とする、改変体を提供する。
Latest bibliographic data on file with the International Bureau